A phase III, 24 week, multi-centre, randomised, double-blind, parallel group, dose escalation study of Avandamet (rosiglitazone/metformin) and high dose metformin monotherapy in subjects with poorly controlled type 2 diabetes mellitus
Diabetes Mellitus, Type 2
Phase 3
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
November 2014